近日，镁信健康正式向港交所递交招股书，开启其赴港上市征程，高盛（亚洲）、中金公司及汇丰银行 担任联席保荐人。这一动作在健康险领域引发广泛关注，毕竟镁信健康自2017年8月由上药云健康分拆 而来，便凭借"互联网 + 医 + 药 + 险"的创新模式，在行业内迅速崭露头角，立志连接药企、保险公 司、医院和患者服务多方，构建协同共赢的闭环生态。然而，在镁信健康看似光鲜亮丽的背后，实则隐 藏着诸多亟待解决的隐忧与挑战。 融资与估值光环下的亏损困境 参保人数增速放缓的背后，是惠民保产品面临的诸多问题。一方面，健康人群因性价比原因逐渐退出参 保，导致产品赔付率持续攀升。这使得惠民保这块蛋糕难以做大，保司在经营过程中面临较大压力。另 一方面，产品和服务同质化严重，各参与方为了争夺市场份额，纷纷展开价格战，进一步压缩了利润空 间。部分保司自身尚无法实现盈利，已有数十款产品停运，甚至连平安养老、泰康养老等大型保司皆因 高赔付率纷纷退出惠民保业务。截至2024年10月31日，各省、自治区、直辖市共推出298款地方性惠民 保产品，而目前正常运营的仅有199款，三分之一的产品已停止运营。 从镁信健康的招股书数据也能看出端倪，2022年 ...

智药解决方案主要是与药企及保司共同研发多元支付解决方案，共同将医疗产品纳入商业健康险和惠民 保项目。智保解决方案主要支持保司商业健康险及惠民保项目，包括支持保司从精算设计、定价咨询到 营销和分销、理赔处理及用户健康管理等。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 近日，镁信健康向港交所递表，高盛（亚洲）、中金公司及汇丰银行担任联席保荐人。公开资料显示， 镁信健康成立于2017年8月，由上药云健康分拆而来，采用"互联网+医+药+险"模式，致力于连接药 企、保险公司、医院和患者服务多方闭环，促进医疗体系相关各方实现协同和共赢。 IPO前，镁信健康共完成7轮融资，估值约117亿元，上海医药、蚂蚁集团为投资方。需要关注的是，在 背靠上海医药与蚂蚁集团双巨头，七年融资超百亿的光环背后，公司目前仍存在诸多隐忧。2022 年-2024年，公司3年累亏超8亿元，经营活动现金流连续三年净流出，且核心业务遭遇监管重拳与市场 萎缩的双重压力。 惠民保陷增长瓶颈 盈利难题仍待解 从业务性质看，镁信健康属于健康险TPA（第三方管理公司），主营业务包括智药解决方案、智保解决 方案、面向消费者的服务三大板 ...

Company Overview - On June 30, 2023, the company, Shanghai Magnesium Health Technology Group Co., Ltd., submitted its prospectus to the Hong Kong Stock Exchange for an IPO, with Goldman Sachs (Asia), CICC, and HSBC as joint sponsors [1] - Established in 2017, the company is the largest pharmaceutical multi-payment platform in China, aiming to address financing and payment challenges faced by patients, insurers, and pharmaceutical companies [1] - The company leverages AI technology to reconstruct the medical payment ecosystem, achieving collaboration and win-win outcomes among stakeholders in the healthcare system [1] Business Solutions - The company has developed two major industry solutions: - The Smart Drug Solution provides pharmaceutical companies with commercialization services covering the entire product lifecycle, facilitating the entry of innovative drugs into diverse payment channels and enhancing patient management efficiency [1] - The Smart Insurance Solution offers end-to-end support for insurance companies, including actuarial design, pricing consultation, marketing distribution, claims processing, and health management, promoting innovation and operational improvement in health insurance [1] - The company also launched a one-stop service platform called "Yima Zhifu," integrating resources from pharmaceuticals, healthcare, and insurance to provide users with more payment options, ultimately enhancing access to quality medical products and services for patients and their families [1] Market Position and Financial Performance - According to Frost & Sullivan, as of December 31, 2024, the company is the largest provider of innovative drug and device solutions in China, and the largest provider of innovative health insurance solutions by the number of policies served [2] - The company has served approximately 393 million insurance policies and collaborated with over 140 pharmaceutical companies, including 90% of the top 20 global pharmaceutical companies by revenue, and over 90 insurance companies, including 100% of the top 20 insurance companies in China by premium income [2] - In 2024, the company helped approximately 40% of the newly listed innovative Class 1 drugs in China, saving patients around RMB 6.7 billion in out-of-pocket expenses [2] - The company achieved a revenue of RMB 2.035 billion in 2024, with a compound annual growth rate of approximately 38% from 2022 to 2024, indicating sustainable growth potential in its innovative business model [2] Industry Outlook - The Frost & Sullivan report predicts that the market size for innovative drugs and devices in China will grow from RMB 162 billion in 2024 to RMB 410.2 billion by 2030, with a compound annual growth rate of 16.7% [3] - The commercial health insurance market in China is expected to expand from RMB 977.3 billion to RMB 2.36 trillion during the same period, with a compound annual growth rate of 15.8% [3] - This structural growth is supported by the "Healthy China 2030" national strategy, which promotes a multi-tiered medical security system, and aligns with the public's urgent demand for accessible quality healthcare services [3] - The company is positioned within the pharmaceutical multi-payment platform sector, effectively addressing public concerns regarding high medical costs and medication accessibility through AI innovation, aligning its business strategy with industry trends, policy directions, and societal needs [3]

6月17日，平安健康保险股份有限公司 （以下简称"平安健康险"）与优家健康（国际）有限公司（以下 简称"优家健康"）于香港科学园举办大湾区健康服务产品合作发布会，推出行业首个一站式跨境医疗服 务产品—"健康医+1，湾区家到家"。该产品将整合内地与香港优质医疗资源，为客户提供门诊协助、专 家会诊、极速陪诊、到院交通协助、住院协助等全方位就医服务，让客户可以从家出发到医院，再从医 院安心回家，无缝衔接，为大湾区医疗服务跨境衔接向纵深发展提供了新方案。 平安健康险总经理助理林晟在发布会致辞中表示，平安健康险积极响应"健康湾区"建设号召，推动优质 医疗服务资源互联互通，满足了广大民众日益蓬勃的跨境就医服务需求。平安健康险期待以"健康医 +1，湾区家到家"跨境医疗服务为起点，持续推动湾区优质医疗资源共建共享，为"健康湾区"建设"加速 度"贡献平安力量！ 图：平安健康险总经理助理林晟先生致辞 优家健康首席执行官郑铭恩先生表示，很高兴能与平安健康险达成战略合作，相信双方在大湾区的医疗 健康资源整合能够为客户提供'1+1>2'的服务效益，携手打造大湾区跨境医疗服务标杆。 优质医疗资源深度融合 打造跨境健康服务新标杆 近年来， ...

重磅利好来了， 中国民生保障体系从"兜底型"向"发展型"跃迁。 6 月 9 日，据新华社等权威媒体披露，中共中央办公厅、国务院办公厅联合印发《关于进一步保障和改善民生 着力解决群众急难愁盼的意 见》（以下简称《意见》）。 机构认为，《意见》的出台标志着在人口结构变化与消费升级的双重背景下， 政策红利将加速释放，为教育、医疗、养老、社区服务等产 业打开万亿级增长空间。 // 4大维度重塑民生保障体 系 // 1、社会保障公平性显著增强 《意见》明确提出" 全面取消在就业地参加社会保险的户籍限制"，打破城乡二元壁垒，推动劳动力要素自由流动。 据新华社报道，政策还将支持有条件地区将生育保险生育津贴直接发放至参保人账户，并合理提高最低工资标准。 中证网分析称， 这一举措将直接降低企业用工成本中的隐性负担，同时增强劳动者消费能力，预计每年释放约 2000 亿元潜在消费力。 2、公共服务均衡化加速推进 文件要求"以县域为基本单元，推进公共服务城乡一体化"，并推动人口流入地城市"一城一策"制定常住地服务标准。医疗、教育等资源将 向中西部及县域倾斜，例如 新建改扩建 1000 所以上优质普通高中，新增高等教育资源向中西部人口 ...

Core Insights - The article discusses the challenges and opportunities in making innovative drugs accessible to the general public, emphasizing the need for a diversified payment system alongside basic medical insurance [1] - The role of commercial health insurance is highlighted as a promising solution to bridge the gap in healthcare access, particularly for innovative drugs [1][2] Group 1: Market Overview - The innovative drug sales market in China is projected to reach 162 billion yuan in 2024, representing a 16% year-on-year growth [1] - Personal cash payments are expected to account for approximately 78.6 billion yuan, making up 49% of the market, while commercial health insurance expenditures are anticipated to be around 12.4 billion yuan, or 7.7% [1] Group 2: Challenges in Commercial Health Insurance - The commercial health insurance sector faces challenges such as strict underwriting processes and a focus on healthy individuals, which limits coverage for chronic disease patients and other special groups [1] - The current insurance products primarily cover public hospital services, with limited inclusion of innovative drugs, high-end treatment equipment, and expenses from private hospitals [1] Group 3: Company Initiatives - The company, Mingxin Health, has pioneered commercial health insurance for innovative drugs since 2019, establishing a connection between patients and new drugs outside the basic medical insurance catalog [2] - Mingxin Health is actively developing diverse insurance products tailored for patients with chronic diseases and the elderly, aiming to expand the funding scale for innovative drug payments [2] Group 4: Technological Advancements - The company leverages technology, such as the Yima Direct Payment platform, to enhance the insurance claims process across various healthcare scenarios, including outpatient, inpatient, and pharmacy services [3] - Future innovations will include the application of AI to improve user experience in claims processing, transforming commercial insurance from a mere payment tool into a value engine within the medical innovation ecosystem [3]

在张小栋看来，当商保不再仅是"支付工具"，而是深度融入医 药创新生态时，便能成为打通供需的"价值引擎"，有助于真正 实现"患者可及、医保基金可持续、商业保险可作为、生物制 药可创新"的共赢局面。 作者：姜鑫 封图：受访者供图 编者按 中国医疗体制改革正驶入深水区。这场以"价值医疗"为核心的改革浪潮，正在重新定义"保 障"的边界，它不仅重塑了14亿人的健康服务版图，更将商业健康险推向了多层次医疗保障体 系的关键位置——既是医保的"补位者"，亦是医疗资源的"整合者"，更是创新支付与健康管 理的"探路人"。 《未来保障谈》栏目立足医改与健康险变革，通过对话商业健康险领域资深人士试图厘清一些 问题：保险如何借力特需医疗、创新药械支付打开差异化服务空间？当医保支付方式改革倒逼 医疗控费，保险能否通过数据共享与医院共建"风险共担"模式？在老龄化与慢病人数增多的 背景下，保险又如何从"风险补偿者"向"健康管理者"转型？保险与医疗如何实现深度融合， 以满足居民未来保障的新需求？ 2025年5月20日，三生制药宣布与辉瑞达成一项总额高达60.5亿美元的授权协议，创下了中国创新 药对外授权交易的新纪录。 三生制药及附属子公司将向 ...

Group 1 - The core viewpoint of the articles revolves around the transformation of China's healthcare system, emphasizing the role of commercial health insurance as a key player in the multi-tiered medical security system, acting as a complement to basic medical insurance and innovating payment and health management solutions [2][4][12] - The commercial health insurance sector is expected to grow significantly, with projections indicating that the market for innovative drugs in China will reach 162 billion yuan in 2024, reflecting a 16% year-on-year increase [4] - The integration of commercial health insurance with the medical and pharmaceutical industries is deepening, with companies like Meixin Health acting as connectors to provide diversified payment solutions [4][10] Group 2 - Meixin Health has served 400 million insurance policies over the past eight years, potentially impacting a significant number of patients, and has saved patients 4.5 billion yuan in medical expenses [10] - The company has developed innovative payment solutions, such as financial installment plans for high-cost drugs, which have reduced monthly expenses significantly for patients [7][15] - The introduction of the "One Code Direct Payment" system allows patients to settle medical expenses without upfront payments, enhancing the accessibility of insurance benefits [16] Group 3 - The challenges faced by the pharmaceutical industry include the need for a diversified payment system to ensure that innovative drugs reach patients effectively, especially under the constraints of basic medical insurance [8][9] - The current penetration of commercial health insurance is insufficient, with issues such as limited coverage for high-value innovative drugs and inadequate service levels for elderly and chronic disease patients [12][13] - The future of the pharmaceutical industry will depend on establishing a robust infrastructure that facilitates collaboration between pharmaceutical companies and insurance providers, ensuring that innovative treatments are accessible and affordable for patients [11][14]

可控核聚变｜短期实验堆打开空间，远期商业化星辰大海 我们基于四条逻辑强烈推荐现阶段可控核聚变行业投资机会：①我们判断行业政策信 号将不断明确，后续或有潜在的行业顶层设计或支持资金预期；②我们认为行业具备 强烈的认知差和预期差，市场普遍认为行业兑现较为远期，但我们认为大量订单将进 入集中兑现期；③我们判断基于AI用电视角，核聚变为AI衍生概念，后续外部催化或 将非常明显；④我们判断核聚变行业与三代核电及军工材料公司具备较高业务重叠， 核电及军工材料行业业绩增速明确、估值合理，未来大量公司有望迎业绩和估值共 振。 华鹏伟 ｜中信证券 电新行业首席分析师 S1010521010007 外骨骼机器人｜落地场景丰富，市场空间广阔 外骨骼机器人可为工业、物流、户外运动等多种场景提供助力和为医疗场景满足康养 需求，作为一种人机紧耦合系统受益于AI和工业控制技术的迭代发展。在人口老龄化 背景下，日渐增加的康养需求和日益减少的劳动力为外骨骼机器人的应用打开了广阔 的市场空间。建议关注具备确定性的核心零部件环节和部分相关设备企业。 风险因素：技术迭代不及预期；行业竞争加剧；零部件价格波动；其他技术路线对外 骨骼形成替代的风险。 ...